A.R.T. Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

A.R.T. Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-183,892	Closed	-$1.26M	–	1711
2019 Q3	$1.26M	Buy	+183,892	New	+$1.41M	0.06%	439
2019 Q1	–	Sell	-103,267	Closed	-$1.59M	–	1610
2018 Q4	$1.59M	Buy	+103,267	New	+$2.12M	0.1%	291
2017 Q1	–	Sell	-14,900	Closed	-$540K	–	1708
2016 Q4	$540K	Buy	14,900 +9,100	+157%	+$363K	0.03%	713
2016 Q3	$266K	Buy	+5,800	New	+$303K	0.09%	388
2015 Q4	–	Sell	-414,963	Closed	-$23.4M	–	1710
2015 Q3	$23.4M	Buy	+414,963	New	+$26.9M	0.87%	4
2015 Q1	–	Sell	-53,036	Closed	-$3.05M	–	1681
2014 Q4	$3.05M	Buy	53,036 +30,662	+137%	+$1.71M	0.11%	247
2014 Q3	$1.2M	Sell	22,374 -26,847	-55%	-$1.42M	0.06%	452
2014 Q2	$2.58M	Buy	+49,221	New	+$2.52M	0.13%	214
2013 Q4	–	Sell	-129,978	Closed	-$4.91M	–	1502
2013 Q3	$4.91M	Sell	129,978 -4,408	-3%	-$172K	0.27%	78
2013 Q2	$5.27M	Buy	+134,386	New	+$5.23M	0.17%	170

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return

A.R.T. Advisors's TEVA Position: Q4 2019 in Review

A.R.T. Advisors sold out of Teva Pharmaceuticals (TEVA) in Q4 2019, closing a stake of 183,892 shares — an estimated $1.26M sold.

A.R.T. Advisors first reported a position in TEVA in Q2 2013 and held it in 10 quarters. The position peaked at $23.4M in Q3 2015. 436 funds tracked by Wall St. Rank hold TEVA as of Q4 2019.

A.R.T. Advisors reported no remaining Teva Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
A.R.T. Advisors sold 183,892 Teva Pharmaceuticals shares in Q4 2019, an estimated $1.26M.
A.R.T. Advisors first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 10 quarters.
A.R.T. Advisors's Teva Pharmaceuticals position peaked at $23.4M in Q3 2015.
436 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2019.

Based on A.R.T. Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.